Recombinant Mouse TNFRSF9/CD137 protein (rFc Tag)

种属

Mouse

纯度

>90 %, SDS-PAGE

标签

rFc Tag

生物活性

未测试

Cat no : Eg1627

Print datasheet

Synonyms

4-1BB, 4-1BB ligand receptor, CD137, Ila, Ly63



产品信息

纯度 >90 %, SDS-PAGE
内毒素 <0.1 EU/μg protein, LAL method
生物活性 Not tested
来源 HEK293-derived Mouse TNFRSF9 protein Val24-Leu187 (Accession# P20334) with a rabbit IgG Fc tag at the C-terminus.
基因ID 21942
蛋白编号 P20334
预测分子量 43.8 kDa
SDS-PAGE 48-60 kDa, reducing (R) conditions
组分 Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
复溶 Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
储存条件
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
运输条件 The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

背景信息

CD137, also known as TNFRSF9 or 4-1BB, is an inducible T cell surface receptor which belongs to the tumor necrosis factor receptor superfamily. CD137 is a transmembrane protein expressed on the surface of activated T-cells. In addition, activation-dependent expression of CD137 has also been found in B lymphocytes, monocytes, and diverse nonlymphoid cell types. CD137 provides a co-stimulatory signal that enhances the survival, and differentiation of cells, and has a crucial role in the development of CD8 cytotoxic T cells and anti-tumor immunity. Soluble forms of CD137 (sCD137) are generated by differential splicing and are released by activated lymphocytes. Elevated serum sCD137 level has been associated with some diseases, including rheumatoid arthritis, multiple sclerosis, chronic lymphocytic leukemia, and acute coronary syndrome.

参考文献:

1. Vinay DS. et al. (1998) Semin Immunol. 10(6):481-9. 2. Schwarz H. et al. (1995) Blood. 85(4):1043-52. 3. Nakaima Y. et al. (2013) PLoS One. 8(5):e64425. 4. Michel J. et al. (1998) Eur J Immunol. 28(1):290-5. 5. Sharief MK. et al. (2002) Eur J Neurol. 9(1):49-54. 6. Furtner M. et al. (2005) Leukemia. 19(5):883-5. 7. Yan J. et al. (2013) Clinics (Sao Paulo). 68(2):193-8.